Merrimack Pharmaceuticals since May 2010
Scientist
Brigham and Women's Hospital Jan 2010 - Apr 2010
Postdoctoral Fellow
Acusphere, Inc. Jul 2002 - Sep 2004
Senior Engineer
US Navy Sep 1999 - Jul 2002
Engineering Division Officer
Education:
Massachusetts Institute of Technology 2004 - 2009
PhD, Cartilage Tissue Engineering
Massachusetts Institute of Technology 1998 - 1999
MS, Chemical Engineering Practice
Massachusetts Institute of Technology 1994 - 1998
SB, Chemical Engineering
Skills:
Cell Culture Life Sciences Tissue Engineering Biomedical Engineering Drug Delivery Stem Cells Regenerative Medicine Osteoarthritis Musculoskeletal
Us Patents
Methods And Apparatus For Making Particles Using Spray Dryer And In-Line Jet Mill
Sridhar Narasimhan - Framingham MA, US David Altreuter - Brookline MA, US Paul Kopesky - Quincy MA, US Mark Keegan - Andover MA, US Julie A. Straub - Winchester MA, US Howard Bernstein - Cambridge MA, US
Assignee:
Acusphere, Inc. - Watertown MA
International Classification:
B01D001/16
US Classification:
159 481, 264 12, 159 401
Abstract:
Methods and apparatus are provided for making particles comprising: (a) spraying an emulsion, solution, or suspension, which comprises a solvent and a bulk material (e. g. , a pharmaceutical agent), through an atomizer and into a primary drying chamber, having a drying gas flowing therethrough, to form droplets comprising the solvent and bulk material dispersed in the drying gas; (b) evaporating, in the primary drying chamber, at least a portion of the solvent into the drying gas to solidify the droplets and form particles dispersed in drying gas; and (c) flowing the particles and at least a portion of the drying gas through a jet mill to deagglomerate or grind the particles. By coupling spray drying with “in-line” jet milling, a single step process is created from two separate unit operations, and an additional collection step is advantageously eliminated. The one-step, in-line process has further advantages in time and cost of processing.
Methods And Apparatus For Making Particles Using Spray Dryer And In-Line Jet Mill
Sridhar Narasimhan - Framingham MA, US David Altreuter - Brookline MA, US Paul Kopesky - Quincy MA, US Mark Keegan - Andover MA, US Julie A. Straub - Winchester MA, US Howard Bernstein - Cambridge MA, US
Assignee:
Acusphere, Inc. - Watertown MA
International Classification:
B01D001/16
US Classification:
159 481, 264 12, 159 401
Abstract:
Methods and apparatus are provided for making particles comprising: (a) spraying an emulsion, solution, or suspension, which comprises a solvent and a bulk material (e. g. , a pharmaceutical agent), through an atomizer and into a primary drying chamber, having a drying gas flowing therethrough, to form droplets comprising the solvent and bulk material dispersed in the drying gas; (b) evaporating, in the primary drying chamber, at least a portion of the solvent into the drying gas to solidify the droplets and form particles dispersed in drying gas; and (c) flowing the particles and at least a portion of the drying gas through a jet mill to deagglomerate or grind the particles. By coupling spray drying with “in-line” jet milling, a single step process is created from two separate unit operations, and an additional collection step is advantageously eliminated. The one-step, in-line process has further advantages in time and cost of processing.
Methods And Apparatus For Making Particles Using Spray Dryer And In-Line Jet Mill
Sridhar Narasimhan - Framingham MA, US David Altreuter - Brookline MA, US Paul Kopesky - Quincy MA, US Mark Keegan - Andover MA, US Julie A. Straub - Winchester MA, US Howard Bernstein - Cambridge MA, US
Assignee:
Acusphere, Inc. - Watertown MA
International Classification:
F26B003/08
US Classification:
34360, 159 481
Abstract:
Methods and apparatus are provided for making particles comprising: (a) spraying an emulsion, solution, or suspension, which comprises a solvent and a bulk material (e. g. , a pharmaceutical agent), through an atomizer and into a primary drying chamber, having a drying gas flowing therethrough, to form droplets comprising the solvent and bulk material dispersed in the drying gas; (b) evaporating, in the primary drying chamber, at least a portion of the solvent into the drying gas to solidify the droplets and form particles dispersed in drying gas; and (c) flowing the particles and at least a portion of the drying gas through a jet mill to deagglomerate or grind the particles. By coupling spray drying with “in-line” jet milling, a single step process is created from two separate unit operations, and an additional collection step is advantageously eliminated. The one-step, in-line process has further advantages in time and cost of processing.
Porous Cox-2 Inhibitor Matrices And Methods Of Manufacture Thereof
David Altreuter - Brookline MA, US Julie Straub - Winchester MA, US Howard Bernstein - Cambridge MA, US Donald Chickering - Framingham MA, US Paul Kopesky - Quincy MA, US Greg Randall - Somerville MA, US
Assignee:
Acusphere, Inc.
International Classification:
A61K031/415 A61K009/20
US Classification:
424/465000, 514/406000
Abstract:
One or more COX-2 inhibitors are provided in a porous matrix form wherein the dissolution rate of the drug is enhanced when the matrix is contacted with an aqueous medium. The porous matrix yields upon contact with an aqueous medium nanoparticles and microparticles of COX-2 inhibitors having a mean diameter between about 0.01 and 5 m and a total surface area greater than about 0.5 m/mL. The dry porous matrix preferably is in a dry powder form having a TAP density less than or equal to 1.0 g/mL. The porous COX-2 inhibitor matrices preferably are made using a process that includes (i) dissolving one or more COX-2 inhibitors in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of COX-2 inhibitors. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug.
Methods And Apparatus For Making Particles Using Spray Dryer And In-Line Jet Mill
Donald Chickering - Framingham MA, US Sridhar Narasimhan - Framingham MA, US David Altreuter - Brookline MA, US Paul Kopesky - Quincy MA, US Mark Keegan - Andover MA, US Julie Straub - Winchester MA, US Howard Bernstein - Cambridge MA, US
International Classification:
B01J023/00
US Classification:
502314000
Abstract:
Methods and apparatus are provided for making particles comprising: (a) spraying an emulsion, solution, or suspension, which comprises a solvent and a bulk material (e.g., a pharmaceutical agent), through an atomizer and into a primary drying chamber, having a drying gas flowing therethrough, to form droplets comprising the solvent and bulk material dispersed in the drying gas; (b) evaporating, in the primary drying chamber, at least a portion of the solvent into the drying gas to solidify the droplets and form particles dispersed in drying gas; and (c) flowing the particles and at least a portion of the drying gas through a jet mill to deagglomerate or grind the particles. By coupling spray drying with “in-line” jet milling, a single step process is created from two separate unit operations, and an additional collection step is advantageously eliminated. The one-step, in-line process has further advantages in time and cost of processing.
- Cambridge MA, US Dmitri B. KIRPOTIN - Revere MA, US Paul KOPESKY - Lexington MA, US Alexey Alexandrovich LUGOVSKOY - Belmont MA, US Rachel RENNARD - Stoneham MA, US Birgit M. SCHOEBERL - Cambridge MA, US
Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided.
- Cambridge MA, US Dmitri B. Kirpotin - Revere MA, US Paul Kopesky - Lexington MA, US Alexey Lugovskoy - Woburn MA, US Rachel Rennard - Stoneham MA, US
Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided.